Arndt Schottelius, MD, PhD, Director Non-Clinical Drug Development, Genentech will provide insights to the decision making essential in taking a drug candidate from the research lab to drug development. Steps such as cost and risk analysis are discussed for making these crucial decisions on promising future cures.
A panel consisting of representatives of a Venture Capitalist, Jerini, a German Biotech company, and other local Bay Area Biotech companies will be discussing their criteria for funding drug development, presenting their process and expertise. This will provide some lively discussion post presentation.
Complimentary appetizers and drinks will be served.
DISCLAIMER: Our aim is to continuously provide our
progressive audience with an open and interactive medium to view
and share relevant,
beneficial and interesting "career, economic, lifestyle and
networking" listings, ads, content and resources.
While the above information may be accurate and viable, the role
of Minority Professional Network, Inc. (MPN) is
strictly as a communications medium, and we do not
accept any responsibility for
cancellation, changes, errors, omissions, inconveniences, or any other form
of liability for any content
displayed or disseminated via our web sites, or e-marketing or social media
promotional services.
If there are any
doubts, we
encourage you to conduct additional research or contact the listed host or responsible entity.
CLICK HERE to inform us about any ads, listings or content
which appear to be
inappropriate,
fraudulent or misleading, or inconsistent with our theme and focus.